Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Debate

Tracing the path of cancer initiation: the AA protein-based model for cancer genesis

Author: Adouda Adjiri

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Cancer is a defiant disease which cure is still far from being attained besides the colossal efforts and financial means deployed towards that end. The continuing setbacks encountered with today’s arsenal of anti-cancer drugs and cancer therapy modalities; show the need for a radical approach in order to get to the root of the problem. And getting to the root of cancer initiation and development leads us to challenge the present dogmas surrounding the pathogenesis of this disease.

Results

This comprehensive analysis brings to light the following points: (i) Cancer with its plethora of genetic and cellular symptoms could originate from one major event switching a cell from normalcy-to-malignancy; (ii) The switching event is postulated to involve a pathological breakup of a non-mutated protein, called here AA protein, resulting in the acquisition of new cellular functions present only in cancer cells; (iii) Following this event, DNA mutations begin to accumulate as secondary events to ensure perpetuity of cancer. Supporting arguments for this protein-based model come mainly from these observations: (i) The AA protein-based model reconciles together the clonal-and-stem cell theories into one inclusive model; (ii) The breakup of a normal protein could be behind the cancer-linked inflammation symptom; (iii) Cancer hallmarks are but adaptive traits, earned as a result of the switch from normalcy-to-malignancy.

Conclusions

Adaptation of cancer cells to their microenvironment and to different anti-cancer drugs is deemed here as the ultimate cancer hallmark, that needs to be understood and controlled. This adaptive power of cancer cells parallels that of bacteria also known with their resistance to a large range of substances in nature and in the laboratory. Consequently, cancer development could be viewed as a backward walk on the line of Evolution. Finally this unprecedented analysis demystifies cancer and puts the finger on the core problem of malignancy while offering ideas for its control with the ultimate goal of leading to its cure.

Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790–801.PubMedCrossRef

Adjiri A. Identifying and targeting the cause of cancer is needed to cure cancer. Oncol Ther. 2016;4:17. https://doi.org/10.1007/s40487-015-0015-6.PubMedCrossRef

Adjiri A. DNA mutations may not be the cause of cancer. Oncol Ther. 2017;5(1):85–101. https://doi.org/10.1007/s40487-017-0047-1.PubMedCrossRef

Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381–8.PubMedCrossRef

Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res. 2014;20:540–7.PubMedCrossRef

Silk AD, Zasadil LM, Holland AJ, et al. Chromosome mis-segregation rate predicts whether aneuploidy will promote or suppress tumors. Proc Natl Acad Sci U S A. 2013;110(44):E4134–41.PubMedPubMedCentralCrossRef

Baylin SB, Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer. 2011;11:726–34. https://doi.org/10.1038/nrc3130.PubMedPubMedCentralCrossRef

Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. Nature Rev Cancer. 2002;2(5):331–41.CrossRef

Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340–4. https://doi.org/10.1126/science.1193494.PubMedCrossRef

10.

Zhu K, Liu Q, Zhou Y, et al. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics. 2015;16(Suppl7):S8. https://doi.org/10.1186/1471-2164-16-S7-S8.PubMedPubMedCentralCrossRef

11.

Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in theevolution of gliomas. Cancer Sci. 2009;100(12):2235–41. https://doi.org/10.1111/j.1349-7006.2009.01308.x.PubMedCrossRef

12.

Nguyen KSH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–9. https://doi.org/10.3816/CLC.2009.n.039.PubMedPubMedCentralCrossRef

13.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761–74. https://doi.org/10.1038/nrc3106.PubMedPubMedCentralCrossRef

14.

Miller TW, Rexer BN, Garrett JT, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13:224.PubMedPubMedCentralCrossRef

15.

Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283(2):125–34. https://doi.org/10.1016/j.canlet.2009.01.022.PubMedCrossRef

16.

Hsieh AL, Walton ZE, Altman BJ, et al. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11–21.PubMedPubMedCentralCrossRef

17.

Wang TJ, Huang MS, Hong CY, et al. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma Tumorigenicity in Situ. Biohem Biophys Res Commun. 2001;287 (1:173–80.CrossRef

18.

Sherr CJ. Principles of tumor suppression. Cell. 2004;116:235–46.PubMedCrossRef

19.

Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther. 2008;8(1):33–42. https://doi.org/10.1586/14737140.8.1.33.PubMedCrossRef

20.

Martinez LA. Mutant p53 and ETS2, a tale of reciprocity. Front Oncol. 2016;6:35. https://doi.org/10.3389/fonc.2016.00035.PubMedPubMedCentralCrossRef

21.

Xie Y, Ma X, Gu L, et al. Prognostic and Clinicopathological significance of Survivin expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2016;6:29794. https://doi.org/10.1038/srep29794.PubMedPubMedCentralCrossRef

22.

Janiec-Jankowska A, Konopka B, Goluda C, et al. TP53 mutations in endometrial cancers: relation to PTEN gene defects. Int J Gynecol Cancer. 2010;20(2):196–202.PubMedCrossRef

23.

Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in Colon Cancer by mutations in β-catenin or APC. Science. 1997;275(5307):1787–90. https://doi.org/10.1126/science.275.5307.1787.PubMedCrossRef

24.

He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMedCrossRef

25.

van de Wetering M, de Lau W, Clevers H. WNT signaling and lymphocyte development. Cell. 2002;109:S13–9.PubMedCrossRef

26.

Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159–69. https://doi.org/10.1016/j.devcel.2008.01.013.PubMedCrossRef

27.

Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479–91.PubMedPubMedCentralCrossRef

28.

Lewis CM, Cler LR, Bu DW, et al. Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk. Clin Cancer Res. 2005;11:166–72.

29.

Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res. 2006;12(22):6626–36.PubMedCrossRef

30.

Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27(41):5443–53.PubMedCrossRef

31.

Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):8–9.CrossRef

32.

Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–58.PubMedPubMedCentralCrossRef

33.

Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40.PubMedCrossRef

34.

Gosselin K, Martien S, Pourtier A, et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res. 2009;69:7917–25.PubMedCrossRef

35.

Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22(16):4212–22.PubMedPubMedCentralCrossRef

36.

Rheinwald JG, Hahn WC, Ramsey MR, et al. A Two-Stage, p16INK4A- and p53-Dependent Keratinocyte Senescence Mechanism That Limits Replicative Potential Independent of Telomere Status. Mol Cell Biol. 2002;22(14):5157–72. https://doi.org/10.1128/MCB.22.14.5157-5172.2002.PubMedPubMedCentralCrossRef

37.

Campisi J. Aging, cellular senescence, and Cancer. Annu Rev Physiol. 2013;75:685–705. https://doi.org/10.1146/annurev-physiol-030212-183653.PubMedCrossRef

38.

Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8:18–30.PubMedCrossRef

39.

Capell BC, Drake AM, Zhu J, et al. MLL1 is essential for the senescence-associated secretory phenotype. Genes Dev. 2016;30:321–36.PubMedPubMedCentralCrossRef

40.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.PubMedCrossRef

41.

Muller D, Breathnach R, Engelmann A, et al. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer. 1991;48:550–6.PubMedCrossRef

42.

Wolf C, Rovyer N. Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumour progression. Proc Natl Acad Sci U S A. 1993;90:1843–7.PubMedPubMedCentralCrossRef

43.

Newell KJ, Witty JP, Rodgers WH, et al. Expression and localisation of matrix-degrading metalloproteinases during colorectal tumourigenesis. Mol Carcinog. 1994;10:199–206.PubMedCrossRef

44.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRef

45.

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.PubMedCrossRef

46.

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.PubMedCrossRef

47.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedPubMedCentralCrossRef

48.

Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.PubMedCrossRef

49.

Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21–22):705–12.PubMedCrossRef

50.

Sedelnikova OA, Horikawa I, Zimonjic DB, et al. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double strand breaks. Nat Cell Biol. 2004;6(2):168–70.PubMedCrossRef

51.

Passos JF, Saretzki G, von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Res. 2007;35(22):7505–13.PubMedPubMedCentralCrossRef

52.

Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463–77.PubMedCrossRef

53.

Codogno P, Mehrpour M, Proikas-Cezanne T. Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol. 2012;13:7–12. https://doi.org/10.1038/nrm3249.CrossRef

54.

Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol. 2007;7:767–77. https://doi.org/10.1038/nri2161.PubMedCrossRefPubMedCentral

55.

Ma Y, Galluzzi L, Zitvogel L, et al. Autophagy and Cellular Immune Responses. Immunity. 2013;39:211–27. https://doi.org/10.1016/j.immuni.2013.07.017.PubMedCrossRef

56.

Degenhardt K, Chen G, Lindsten T, et al. BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell. 2002;2:193–203.PubMedCrossRef

57.

Guo JY, Chen HY, Mathew R, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011;25:460–70.PubMedPubMedCentralCrossRef

58.

Yang S, Wang X, Contino G, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717–29.PubMedPubMedCentralCrossRef

59.

Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol. 2013;13:722–37. https://doi.org/10.1038/nri3532.PubMedPubMedCentralCrossRef

60.

Rodriguez OC, Choudhury S, Kolukula V, et al. Dietary down-regulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012;11:4436–46.PubMedPubMedCentralCrossRef

61.

Choudhury S, Kolukula VK, Preet A, et al. Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy? Cell Cycle. 2013;12:1022–9.PubMedPubMedCentralCrossRef

62.

Garufi A, Pucci D, D’Orazi V, et al. Degradation of mutant p53H175 protein by Zn (II) through autophagy. Cell Death Disease. 2014;5:e1271. https://doi.org/10.1038/cddis.2014.217.PubMedPubMedCentralCrossRef

63.

Lazova R, Camp RL, Klump V, et al. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res. 2012;18:370–9.PubMedCrossRef

64.

Mikhaylova O, Stratton Y, Hall D, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532–46. https://doi.org/10.1016/j.ccr.2012.02.019.PubMedPubMedCentralCrossRef

65.

Onodera J, Ohsumi Y. Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation. J Biol Chem. 2005;280:31582–6. https://doi.org/10.1074/jbc.M506736200.PubMedCrossRef

66.

Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51–64. https://doi.org/10.1016/j.ccr.2006.06.001.PubMedPubMedCentralCrossRef

67.

Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537–48. https://doi.org/10.1101/gad.1756509.PubMedPubMedCentralCrossRef

68.

Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell. 2013;155:1216–9. https://doi.org/10.1016/j.cell.2013.11.019.PubMedPubMedCentralCrossRef

69.

Cruickshanks HA, McBryan T, Nelson DM, et al. Senescent cells harbour features of the cancer epigenome. Nat Cell Biol. 2013;15(12):1495–506. https://doi.org/10.1038/ncb2879.PubMedPubMedCentralCrossRef

70.

Qureshi-Baig K, Ullmann P, Haan S, et al. Tumor-initiating cells: a criTICal review of isolation approaches and new challenges in targeting strategies. Mol Cancer. 2017;16:40–56. https://doi.org/10.1186/s12943-017-0602-2.PubMedPubMedCentralCrossRef

71.

Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMedCrossRef

72.

Fulawka L, Donizy P, Halon A. Cancer stem cells-the current status of an old concept: literature review and clinical approaches. Biol Res. 2014;47:66.PubMedPubMedCentralCrossRef

73.

Kim W-T, Ry CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50(6):285–98.PubMedPubMedCentralCrossRef

74.

Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006;124:1111–5.PubMedCrossRef

75.

Bianco C, Salomon DS. Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin Ther Pat. 2010;20(12):1739–49. https://doi.org/10.1517/13543776.2010.530659.PubMedPubMedCentralCrossRef

76.

Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593–8.PubMedPubMedCentralCrossRef

77.

Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–9.PubMedCrossRef

78.

Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010;18:510–23.PubMedPubMedCentralCrossRef

79.

Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6:2332–8.PubMedCrossRef

80.

Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.PubMedCrossRef

81.

Vermeulen L, Sprick MR, Kemper K, et al. Cancer stem cells – old concepts, new insights. Cell Death Differ. 2008;15:947–58.PubMedCrossRef

82.

van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728:23–34. https://doi.org/10.1016/j.mrrev.2011.05.002.PubMedPubMedCentralCrossRef

83.

Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature. 2005;438:820–7.PubMedPubMedCentralCrossRef

84.

Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science. 1982;217:361–3.PubMedCrossRef

85.

Bernards R, Weinberg RA. Metastasis genes: A progression puzzle. Nature. 2002;418(6900):823. https://doi.org/10.1038/418823a.PubMedCrossRef

86.

Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49.PubMedCrossRef

87.

Wels J, Kaplan RN, Rafii S, et al. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008;22:559–74.PubMedPubMedCentralCrossRef

88.

Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature. 2004;430:973–4.PubMedCrossRef

89.

Wyckoff B, Wang Y, Lin EY, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649–56.PubMedCrossRef

90.

Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–3.CrossRef

91.

Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.PubMedCrossRef

92.

Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007;26:319–31.PubMedCrossRef

93.

Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547–51.PubMedCrossRef

94.

McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21:418–24.PubMedPubMedCentralCrossRef

95.

Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef

96.

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.PubMedCrossRef

97.

Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–74.PubMedCrossRef

98.

Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal–amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 2003;160:267–77.PubMedPubMedCentralCrossRef

99.

Lewis K, Shan Y. Why tolerance invites resistance. Science. 2017;355(6327):796. https://doi.org/10.1126/science.aam7926.PubMedCrossRef

100.

Levin-Reisman I, Ronin I, Gefen O, et al. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017;355(6327):826–30. https://doi.org/10.1126/science.aaj2191.PubMedCrossRef

101.

Baer CF, Miyamoto MM, Denver DR. Mutation rate variation in multicellular eukaryotes: causes and consequences. Nature Rev Genet. 2007;8:619–31.PubMedCrossRef

102.

Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol. 2000;26(4):405–17. https://doi.org/10.1053/ejso.1999.0907.PubMedCrossRef

103.

Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 1989;28(1):113–21. https://doi.org/10.3109/02841868909111193.PubMedCrossRef

104.

Bates RC, Edwards NS, Yates JD. Spheroids and cell survival. Crit Rev Oncol Hematol. 2000;36:61–74.PubMedCrossRef

105.

He Z, Kannan N, Nemirovsky O, et al. BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells. Oncotarget. 2017;8(20):32461–75.PubMedPubMedCentral

106.

Morroni M, Giordano A, Zingaretti MC, et al. Reversible trans-differentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A. 2004;101:16801–6.PubMedPubMedCentralCrossRef

107.

Murga M, Fernandez-Capetillo O. Genomic instability: on the birth and death of cancer. Clin Transl Oncol. 2007;9:216–20. https://doi.org/10.1007/s12094-007-0042-3.PubMedCrossRef

108.

Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37(5):961–76.PubMedCrossRef

109.

Dolcetti R, de Rossi A. Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. Med Res Rev. 2012;32:233–53.PubMedCrossRef

Title: Tracing the path of cancer initiation: the AA protein-based model for cancer genesis
Author: Adouda Adjiri
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4739-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Age-related sarcoma patient experience: results from a national survey in England

Survival after the diagnosis of breast or colorectal cancer in the GAZA Strip from 2005 to 2014

Activation of antioxidant defences of human mammary epithelial cells under leptin depend on neoplastic state

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair

Keynote webinar | Spotlight on antibody–drug conjugates in cancer